RRIDs were included in the Cancer Immunology Research paper "Identification of Immunogenic MHC Class II Human H…" (https://t.co/CCy7tEJ90P). RRIDs like this improve reproducibility in scientific research. #ReproducibleResearch #accelerateopenscience
RRIDs were included in the Cancer Immunology Research paper "Identification of Immunogenic MHC Class II Human H…" (https://t.co/CCy7tEJ90P). RRIDs like this improve reproducibility in scientific research. #ReproducibleResearch #reproducibility
RT @CIR_AACR: Interested in the #AACR22 #CancerVaccine session? Check out study ID'ing immunogenic, promiscuous MHCII HER3 peptides that in…
RT @CIR_AACR: Interested in the #AACR22 #CancerVaccine session? Check out study ID'ing immunogenic, promiscuous MHCII HER3 peptides that in…
Interested in the #AACR22 #CancerVaccine session? Check out study ID'ing immunogenic, promiscuous MHCII HER3 peptides that induce Th1 responses in both preventative and therapeutic settings! By Basu, Czerniecki et al. https://t.co/COZeJ72iB0 @DrJashDatta @
Multiple immunogenic, promiscuous #MHCII #HER3 peptides are ID'd & shown to induce potent human & mouse #CD4+ #Th1 responses. Data highlight HER3 as a potential target in both a preventative & therapeutic setting. https://t.co/P9gbEPOl3e @DrJas
RT @DrJashDatta: Almost 6 years after I started this work as a postdoc @PennCancer @pennsurgery! Now published in @CIR_AACR - congrats to B…
RT @DrJashDatta: Almost 6 years after I started this work as a postdoc @PennCancer @pennsurgery! Now published in @CIR_AACR - congrats to B…
RT @DrJashDatta: Almost 6 years after I started this work as a postdoc @PennCancer @pennsurgery! Now published in @CIR_AACR - congrats to B…
Almost 6 years after I started this work as a postdoc @PennCancer @pennsurgery! Now published in @CIR_AACR - congrats to Brian Czerniecki and his team @MoffittNews. High fidelity discovery of immunogenic HER3 peptides for cancer vaccine development https:/
Identification of immunogenic MHC class II human HER3 peptides that mediate anti-HER3 CD4+ Th1 responses and potential use as a cancer vaccine https://t.co/FZNLmy7H9v
New article: Identification of immunogenic MHC class II human HER3 peptides that mediate anti-HER3 CD4+ Th1 responses and potential use as a cancer vaccine https://t.co/dfZrSXIeGJ #melanoma #oncology https://t.co/mKRuqn2H4B